A Preliminary Evaluation on the Antifungal Efficacy of VT-1161 against Persister Candida albicans Cells in Vulvovaginal Candidiasis

Persister cells are a small fraction of the microbial population that survive lethal concentrations of antimicrobial agents. causes vaginal candidiasis, including recurrent vulvovaginal candidiasis, and may survive common antifungal treatments. The triazole VT-1161 is an antifungal agent that specif...

Full description

Saved in:
Bibliographic Details
Published inBiomedicines Vol. 12; no. 2; p. 389
Main Authors Sinoca, Marica, Maione, Angela, Gambino, Edvige, Imparato, Marianna, Galdiero, Marilena, de Alteriis, Elisabetta, Galdiero, Emilia, Guida, Marco
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 07.02.2024
Subjects
Amphotericin B
Antibiotics
Antifungal activity
Antifungal agents
antifungals
Antimicrobial agents
Biofilms
Candida albicans
Candidiasis
Glucose
HaCaT model
Infections
Minimum inhibitory concentration
Pathogenesis
persister cells
recurrent vaginal candidiasis
Vagina
Womens health
St Louis Missouri
United States > US
Detroit Michigan
Germany
Candida albicans
recurrent vaginal candidiasis
antifungals
HaCaT model
biofilms
persister cells
Online AccessGet full text

Cover

More Information
Summary:Persister cells are a small fraction of the microbial population that survive lethal concentrations of antimicrobial agents. causes vaginal candidiasis, including recurrent vulvovaginal candidiasis, and may survive common antifungal treatments. The triazole VT-1161 is an antifungal agent that specifically targets fungal CYP51, as opposed to the human CYP enzyme. This work illustrates a new role of VT-1161 in eradicating the biofilm created from the persister cells of a primary biofilm of a clinical vaginal isolate of . Antifungal activity was determined by the minimum inhibitory concentration (MIC), and the primary biofilm was treated with amphotericin B to obtain persister cells that were able to form a new biofilm. Results obtained using the new azole VT-1161 showed that VT-1161 not only eradicated a secondary biofilm formed from the persister-derived biofilm and counteracted the adhesion of in vitro to human cells but also ameliorated -induced infection in vivo in larvae, suggesting that it could be proposed as an alternative therapeutic strategy for the treatment of recurrent candidiasis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines12020389